Artrya (AYA) Stock Overview
A medical technology company, engages in the development and commercialization of artificial intelligence platform that detects, diagnoses, and address coronary artery disease in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
AYA Community Fair Values
Create NarrativeSee what 20 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Artrya Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$3.27 |
| 52 Week High | AU$6.49 |
| 52 Week Low | AU$2.09 |
| Beta | 0.59 |
| 1 Month Change | -31.87% |
| 3 Month Change | -27.33% |
| 1 Year Change | 48.64% |
| 3 Year Change | 1,157.69% |
| 5 Year Change | n/a |
| Change since IPO | 114.43% |
Recent News & Updates
Recent updates
AYA: New CFO Appointment Will Support Future Earnings Re Rating
Analysts have updated their view on Artrya with a lower implied fair value per share, moving from A$6.62 to about A$5.96. They cite revised assumptions for revenue growth, profit margins and future P/E levels.US CCTA Adoption And New Reimbursement Will Drive Long Term Cardiac AI Potential
Catalysts About Artrya Artrya develops AI-powered cardiac imaging software that helps clinicians assess coronary anatomy, plaque and blood flow from CCTA scans. What are the underlying business or industry changes driving this perspective?We're Hopeful That Artrya (ASX:AYA) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, Artrya ( ASX:AYA...We Think Artrya (ASX:AYA) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Here's Why We're Not Too Worried About Artrya's (ASX:AYA) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...We're Not Very Worried About Artrya's (ASX:AYA) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Shareholder Returns
| AYA | AU Healthcare Services | AU Market | |
|---|---|---|---|
| 7D | -21.8% | -3.5% | -2.0% |
| 1Y | 48.6% | -37.1% | -1.1% |
Return vs Industry: AYA exceeded the Australian Healthcare Services industry which returned -37.1% over the past year.
Return vs Market: AYA exceeded the Australian Market which returned -1.1% over the past year.
Price Volatility
| AYA volatility | |
|---|---|
| AYA Average Weekly Movement | 12.0% |
| Healthcare Services Industry Average Movement | 10.1% |
| Market Average Movement | 9.7% |
| 10% most volatile stocks in AU Market | 16.7% |
| 10% least volatile stocks in AU Market | 4.0% |
Stable Share Price: AYA has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: AYA's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | John Konstantopoulos | www.artrya.com |
Artrya Limited, a medical technology company, engages in the development and commercialization of artificial intelligence platform that detects, diagnoses, and address coronary artery disease in Australia. It offers Salix, a suite of cloud-based software that uses artificial intelligence to automate the detection of coronary artery disease from coronary computed tomography angiography scans to identify and manage patients at risk of a heart attack. The company was incorporated in 2018 and is based in West Perth, Australia.
Artrya Limited Fundamentals Summary
| AYA fundamental statistics | |
|---|---|
| Market cap | AU$532.89m |
| Earnings (TTM) | -AU$25.18m |
| Revenue (TTM) | AU$28.00k |
Is AYA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AYA income statement (TTM) | |
|---|---|
| Revenue | AU$28.00k |
| Cost of Revenue | AU$20.05m |
| Gross Profit | -AU$20.02m |
| Other Expenses | AU$5.16m |
| Earnings | -AU$25.18m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.15 |
| Gross Margin | -71,496.43% |
| Net Profit Margin | -89,939.29% |
| Debt/Equity Ratio | 0% |
How did AYA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/11 17:29 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Artrya Limited is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Melissa Benson | Barrenjoey Markets Pty Limited |
| Martyn Jacobs | Bell Potter |
| Andrew Wilkinson | Venn Brown Pty Ltd |